CDH1 and cancer: Tumors with CDH1 alterations show lower progression-free and disease-specific survival, emphasizing the biological consequences of losing E-cadherin. Moreover, EMT-like changes in LBC may be more subtle than in other cancers, occurring without complete loss of epithelial markers.